LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.
More Information Supplier PageLY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.
More Information Supplier PageLY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.
More Information Supplier PageLY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.
More Information Supplier PageBatimastat (BB-94) is a potent and synthetic inhibitor of a broad spectrum of matrix metalloproteinases (MMPs), including interstitial collagenase (IC50 = 3 nM), stromelysin (IC50 = 20 nM), Mr 72,000 type IV collagenase (IC50 = 4 nM), Mr 92,000 type IV collagenase (IC50 = 4 nM), and matrilysin (IC50 = 6 nM). It is a […]
More Information Supplier PageA nucleoside analog used in the treatment of viral infections (including those caused by human immunodeficiency virus, cytomegalovirus, and herpes virus).
More Information Supplier PageGR 103691 is an effective and selective receptor antagonist of the dopamine D3 receptor (D3DR).
More Information Supplier PageGR 103691 is an effective and selective receptor antagonist of the dopamine D3 receptor (D3DR).
More Information Supplier PageZaleplon is a non-benzodiazepine agent that acts as an agonist at the benzodiazepine site.
More Information Supplier PageZaleplon is a non-benzodiazepine agent that acts as an agonist at the benzodiazepine site.
More Information Supplier Page
